Tonix Pharmaceuticals
TNXP
3 hedge funds and large institutions have $3.53M invested in Tonix Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
290% more capital invested
Capital invested by funds: $906K → $3.53M (+$2.62M)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more funds holding
Funds holding: 2 → 3 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.21M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$606K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$606K |
| 2 |
Jane Street
New York
|
-$38K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$10K |
| 5 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GI
26
Gradient Investments
Arden Hills,
Minnesota
| $2K | – | – | – |
|
27
Morgan Stanley
New York
| $1K | – | – | – |
|
28
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
|
TFS
29
TrustCore Financial Services
Brentwood,
Tennessee
| $1K | – | – | – |
|
30
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
FCH
31
Freestone Capital Holdings
Seattle,
Washington
| $252 | – | – | – |
|
32
Millennium Management
New York
| $68 | – | – | – |
|
|
ARTA
33
A.R.T. Advisors
New York
| – | -$10K | – | – |
|
|
CAN
34
Cetera Advisor Networks
El Segundo,
California
| – | -$3K | – | – |
|
|
35
Jane Street
New York
| – | -$38K | – | – |
|
|
36
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$13K | – | – |
|
TNXP Hedge Fund Activity: Q3 2020 in Review
3 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q3 2020, worth a combined $3.53M — up 290% from $906K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new TNXP positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $1.21M. The largest seller was Citadel Advisors, exiting entirely with an estimated $606K sold.
- 3 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q3 2020, up from 2 in Q2 2020.
- Funds reported $3.53M of Tonix Pharmaceuticals stock for Q3 2020, up 290% quarter-over-quarter.
- 2 funds opened new Tonix Pharmaceuticals positions in Q3 2020 and 1 closed out, a net change of +1 holder.
- The largest Tonix Pharmaceuticals buyer in Q3 2020 was BlackRock, an estimated $1.21M added.
- The largest Tonix Pharmaceuticals seller in Q3 2020 was Citadel Advisors, an estimated $606K sold.
Based on aggregated 13F filings for Q3 2020.